Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040156

« Back to Dashboard

NDA 040156 describes HYDROXYZINE PAMOATE, which is a drug marketed by Barr, Duramed Pharms Barr, Heritage Pharma, Impax Labs Inc, Ivax Sub Teva Pharms, Par Pharm, Sandoz, Superpharm, Vangard, and Watson Labs, and is included in thirty-four NDAs. It is available from thirty-six suppliers. Additional details are available on the HYDROXYZINE PAMOATE profile page.

The generic ingredient in HYDROXYZINE PAMOATE is hydroxyzine pamoate. There are nineteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the hydroxyzine pamoate profile page.

Summary for 040156

Tradename:	HYDROXYZINE PAMOATE
Applicant:	Impax Labs Inc
Ingredient:	hydroxyzine pamoate
Patents:	0
Therapeutic Class:	Antiemetics Respiratory Tract Agents
Formulation / Manufacturing:	see details

Pharmacology for NDA: 040156

Mechanism of Action	Histamine Receptor Antagonists

Suppliers and Packaging for NDA: 040156

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
HYDROXYZINE PAMOATE	hydroxyzine pamoate	CAPSULE;ORAL	040156	ANDA	Impax Generics	0115-1670	N	0115-1670-01
HYDROXYZINE PAMOATE	hydroxyzine pamoate	CAPSULE;ORAL	040156	ANDA	Impax Generics	0115-1670	N	0115-1670-02

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 25MG HCL
Approval Date:	Jul 15, 1996	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 50MG HCL
Approval Date:	Jul 15, 1996	TE:	AB	RLD:	No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys

Cerilliant

McKinsey

Harvard Business School

Baxter

Merck

Accenture

Chinese Patent Office

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.